Insys Therapeutics Inc. (INSY) Shares Down 2.4%
Insys Therapeutics Inc. (NASDAQ:INSY) shares fell 2.4% during trading on Wednesday . The company traded as low as $14.50 and last traded at $14.57, with a volume of 244,513 shares changing hands. The stock had previously closed at $14.93.
A number of brokerages have commented on INSY. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Insys Therapeutics in a report on Thursday, August 25th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $22.00 price objective (up from $17.00) on shares of Insys Therapeutics in a report on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Insys Therapeutics presently has a consensus rating of “Buy” and an average target price of $24.67.
The stock has a 50 day moving average of $16.21 and a 200-day moving average of $15.56. The company has a market cap of $1.12 billion and a P/E ratio of 23.66.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/insys-therapeutics-inc-insy-shares-down-2-4.html
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.01. The company earned $67.10 million during the quarter, compared to analyst estimates of $66.90 million. The company’s revenue for the quarter was down 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.21 EPS. On average, equities research analysts anticipate that Insys Therapeutics Inc. will post $0.40 earnings per share for the current year.
In related news, VP Daniel Brennan sold 5,781 shares of Insys Therapeutics stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $19.16, for a total transaction of $110,763.96. Following the sale, the vice president now directly owns 1 shares in the company, valued at $19.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 5,700 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average price of $18.57 per share, for a total transaction of $105,849.00. Following the completion of the acquisition, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $593,905.74. The disclosure for this purchase can be found here. Corporate insiders own 69.20% of the company’s stock.
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.